Lloyds Banking Share Discussion Threads

[xxxxxy] 03/8/2020 16:42

Lovely weather in Wales. And a great warm feeling. Brexit Glorious.Wonderful wonderful wonderful Brexit. No DealWTO

[alphorn] 03/8/2020 16:39

Still paddling in circles Pugwash? Lol

[hamhamham1] 03/8/2020 16:36

5 yrs time hopeful estimate.
Lloyds 150p a share
NWG 600p a share
(Both after some buy backs)

[hamhamham1] 03/8/2020 16:32

8% roughly what was lost on results day.
Am happy with a big wad of these.

[chavitravi2] 03/8/2020 16:29

Been out all day. Saw it was just below 26p when I went out. Looks like a 6-7% rise today if this holds.

[hamhamham1] 03/8/2020 16:28

Give it a year or two and then the share buy backs will start. They will reinstate the shareholder value again.
Hopefully similar to Apple, where they are going to buy back 6% of shares each year for next 3-5 years.
SP will be easy three figures medium term.

[thomas4billing] 03/8/2020 16:16

Barclays Capital today reaffirms its overweight investment rating on Lloyds Banking Group PLC ORD (LON:LLOY) and cut its price target to 45p (from 50p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk

[gaffer73] 03/8/2020 16:12

I'd say 15% divi but also 300% capital growth as well.

[mitchy] 03/8/2020 16:07

People are going to look back on these prices and say "why didn't I buy when I had the chance" ?

[dope007] 03/8/2020 15:59

Nah, the real money has been made by the owners of Indian and Chinese sweat shops selling masks

[poikka] 03/8/2020 15:52

You sycophantic slob, Alphorn. Still, I do understand your need for a friend.

Leaving that aside, the real money to be made from this tragedy will be from those pharmas making the drugs and medications necessary to treat all those who will be suffering from the effects of Covid for years to come.

[poikka] 03/8/2020 15:46

"ZERO CHANCE CORONOVIRUS IS NATURAL"

hxxps://www.taiwannews.com.tw/en/news/3979550

[hamhamham1] 03/8/2020 15:09

Can Lloyds get a 8% bounce today?

[alphorn] 03/8/2020 15:08

max - best post today. Thank you.

[maxk] 03/8/2020 15:02

From the ticker:



Gilead Shows the Dangers of Covid-19 Drug Mania -- Heard on the Street
03/08/2020 12:29pm
Dow Jones News

Johnson and Johnson (NYSE:JNJ)
Intraday Stock Chart

Monday 3 August 2020

Click Here for more Johnson and Johnson Charts.By Charley Grant
Researchers are racing to develop a Covid-19 vaccine, and investors are in a mad dash to profit from it. The financial side of this exercise is likely to run into trouble.

Promising news in the hunt for a vaccine continues to pour in. Several companies have revealed encouraging, albeit preliminary, data in clinical trials, and the U.S. government has its wallet wide open to defray research and manufacturing expenses. GlaxoSmithKline and Sanofi said Friday that the U.S. government will pay up to $2.1 billion to develop and manufacture a Covid-19 vaccine. Other companies such as Moderna and AstraZeneca have received similar contracts. These deals include the upfront purchase of hundreds of millions of doses if trials prove successful. Heavyweights Merck & Co. and Johnson & Johnson also have candidates in development.

While it won't be clear if any candidate is successful until at least the fall, investors aren't waiting around. A broad index of biotechnology stocks has surged 65% since March. Within that group, the Covid-19 vaccine makers have led the way, both large and small. The gain in market value for these companies since the spring matches the total value of some major drugmakers that generate roughly $20 billion in annual sales.

There are ample reasons for caution, despite the clearly positive news. For starters, most drug candidates in development don't reach the market. Huge research investments won't change that reality.

And, even if successful, pricing power may not be as strong as investors are hoping. The first round of doses are already paid for and priced into stocks. Pfizer and its partner BioNTech, which didn't take any government research funding, have a contract to deliver 100 million doses for a total of $1.95 billion. That comes out to about $39 per two-dose treatment.

Companies that hope to charge more than that over the long term will need to meet a very high safety and efficacy bar to make their case -- especially those that took public funds upfront. While drug pricing hasn't attracted much scrutiny this election cycle, it has been a recurring theme in American politics with major consequences for shareholders. That dynamic likely makes visions of windfall profits more dream than reality.

Granted, some risk-taking is always necessary to make money in biotech. And story stocks have a way of maintaining their upward momentum while hopes for the future are still intact -- particularly in today's euphoric investing environment.

But investors shouldn't forget that hot drug stocks can suddenly plunge even if things go according to plan. Gilead Sciences shares surged nearly 25% from March to April as anticipation built for its antiviral Covid-19 treatment remdesivir, but the stock has since lost nearly all of that ground. Those losses came despite a string of successes: The drug has been authorized for emergency use, and Gilead began selling it this summer after donating its initial supply. Last week, the company increased the midpoint of its 2020 adjusted profit guidance to $6.95 a share from $6.25.

Don't dismiss the possibility that Gilead's descent will repeat itself on a much larger, uglier scale.

Write to Charley Grant at [e-mail]

[dope007] 03/8/2020 14:54

Apple $440 LOFL's

[carlcjasper] 03/8/2020 14:49

Would they be down 3% today

[alphorn] 03/8/2020 14:49

G2 ...catching you up then.

[carlcjasper] 03/8/2020 14:49

Nice bump up today where's the all the shorts today ?

[grahamite2] 03/8/2020 14:47

You're not quite brain dead, Alphorn. Getting there, though.

[freddie01] 03/8/2020 14:46

Aldi plans to launch Amazon Go-style cashierless stores as it requests product recognition tech

[alphorn] 03/8/2020 14:44

So there is general agreement from the brain dead that David Davis was a weakling without his own opinion.

....now they are all wonderful I presume?

Not the most inquiring of minds here - to be polite.